Rheumatic heart disease (RHD) stands as a chronic, progressive condition arising from rheumatic fever, itself a sequela of untreated or inadequately treated Group A Streptococcus (GAS) pharyngitis. While acute rheumatic fever can manifest with a range of symptoms affecting joints, skin, and the central nervous system, it is the subclinical or clinically apparent carditis that precipitates the long-term damage characteristic of RHD. The pathophysiology of RHD is a complex interplay of direct bacterial effects, an aberrant immune response, and subsequent chronic inflammation, leading to irreversible valvular damage. Understanding this process is crucial for effective prevention, diagnosis, and management of this devastating preventable disease.
The initial insult in the development of RHD is infection with specific strains of GAS, commonly known as "rheumatic strains." These bacteria possess surface antigens, most notably the M protein, which bear structural similarities to host tissues, particularly in the heart valves. Following pharyngeal colonization and infection, the host mounts an immune response. Antibodies are produced against GAS antigens. However, due to molecular mimicry, these antibodies can cross-react with similar epitopes found on host tissues, primarily in the heart. This cross-reactivity is a central tenet of RHD pathophysiology. The immune system, in its attempt to clear the bacterial infection, inadvertently begins to attack the host's own cardiac tissue.
The immune attack is not confined to direct antibody-mediated damage. Cell-mediated immunity also plays a significant role. T-helper cells (CD4+ T cells) are activated by GAS antigens presented on antigen-presenting cells. These activated T cells, along with other inflammatory mediators, orchestrate a broader inflammatory response within the heart. This inflammation, termed carditis, can affect the pericardium (pericarditis), myocardium (myocarditis), and endocardium, with the endocardium, particularly the heart valves, being the most vulnerable. The inflammatory process leads to edema, cellular infiltration (lymphocytes, plasma cells, macrophages), and fibrinoid necrosis of valvular tissue. Characteristic Aschoff bodies, collections of activated macrophages and lymphocytes, are pathognomonic histological findings in acute rheumatic carditis.
These acute inflammatory changes, if recurrent or severe, can lead to chronic valvular damage. The initial inflammation causes the valve leaflets to become thickened, hemorrhagic, and friable. During this phase, vegetations, which are sterile thrombi composed of fibrin and platelets, can form on the damaged valve surfaces, particularly along the lines of closure. These vegetations can embolize, though this is more common in infective endocarditis. More importantly, the repeated bouts of inflammation, often triggered by subsequent GAS infections, lead to fibrosis and scarring of the valve leaflets and the chordae tendineae. This scarring causes contractures, fusion of the leaflets, and shortening and thickening of the chordae tendineae.
The cumulative effect of these pathological changes is valvular dysfunction. The most commonly affected valves are the mitral and aortic valves, with mitral regurgitation and stenosis being the hallmark of RHD. Mitral regurgitation occurs when the scarred and deformed valve leaflets cannot coapt properly, leading to backflow of blood into the left atrium during systole. Mitral stenosis develops when leaflet fusion and chordal thickening restrict the opening of the mitral valve, impeding blood flow from the left atrium to the left ventricle. Aortic regurgitation can also occur due to damage to the aortic valve leaflets, and less commonly, aortic stenosis. These valvular lesions place a significant hemodynamic burden on the heart, leading to left atrial and ventricular enlargement, and eventually, heart failure. The chronic stress on the myocardium can also lead to diastolic and systolic dysfunction.
The recurrent nature of GAS infections in susceptible populations, particularly in areas with poor access to healthcare and crowded living conditions, perpetuates the cycle of inflammation and damage, accelerating the progression of RHD. Each episode of rheumatic fever can cause further valvular injury, exacerbating existing lesions and leading to a more severe and earlier onset of symptoms. This underscores the importance of prompt diagnosis and complete treatment of streptococcal pharyngitis and, critically, secondary prophylaxis with penicillin to prevent recurrent episodes of rheumatic fever.
In summary, rheumatic heart disease is a chronic autoimmune sequela of Group A Streptococcus infection. The pathophysiology is initiated by molecular mimicry between GAS antigens and cardiac tissues, leading to acute carditis characterized by inflammation and the formation of Aschoff bodies. This acute phase can progress to chronic valvular damage through fibrosis, scarring, and leaflet deformities, resulting in valvular regurgitation and/or stenosis. The cumulative hemodynamic stress ultimately leads to cardiac chamber enlargement, dysfunction, and potentially heart failure, making RHD a significant cause of cardiovascular morbidity and mortality worldwide.